PROGRESS PHARMA
Enterprise number 0536258560 · Active (000 Normale toestand)
PROGRESS PHARMA is a naamloze vennootschap registered in Vosselaar, Belgium, incorporated on 27 Jun 2013. Its registered activity is overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied.
Company details
- Enterprise number
- 0536258560 · official register
- Status
- 000 Normale toestand
- Legal form
- Naamloze vennootschap
- Incorporated
- 27 Jun 2013 (13 years)
- Registered address
- 2350 Vosselaar
- Province
- Antwerp
- Activity
- 72190 Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
- Industry
- Scientific research and development
- Accounts overdue
- Yes
Insolvency and register events
No insolvency or liquidation events on record.
Similar companies in Antwerp
- 4Nature Antwerpen
- ADVANCED BIO-POLYMEER TECHNOLOGIES Antwerpen
- ALEXANDER TECHNIEK EDEGEM Edegem
- ALLEGRO Antwerpen
- AMIANTO Aartselaar
- AMYNAS Duffel
- ANTARCTIQ Grobbendonk
- Adrianepoxy Brasschaat
- AgomAb Therapeutics Antwerpen
- All For Research Antwerpen
- Amylla Mortsel
- AnaLIStics Kontich
Questions about PROGRESS PHARMA
What is the enterprise number of PROGRESS PHARMA?
PROGRESS PHARMA is registered under enterprise number 0536258560 in the official register of Belgium. View it at the official register.
Is PROGRESS PHARMA still active?
Yes. PROGRESS PHARMA is registered as active (status: 000 Normale toestand).
Has PROGRESS PHARMA gone bankrupt or into insolvency?
No insolvency, bankruptcy or administration is recorded for PROGRESS PHARMA in the official data.
When was PROGRESS PHARMA founded?
PROGRESS PHARMA was incorporated on 27 Jun 2013.
Where is PROGRESS PHARMA registered?
PROGRESS PHARMA's registered address is in 2350 Vosselaar (Antwerp), Belgium.
Data: FPS Economy – KBO/BCE Open Data (KBO Open Data licence; source: FPS Economy, Crossroads Bank for Enterprises.). National Bank of Belgium – Central Balance Sheet Office web services (NBB-CBSO authentic data, free re-use under the NBB web-service terms.). Last updated 6 Nov 2026.